{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T17:28:40Z","timestamp":1649179720492},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00393-018-0443-4","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T13:38:35Z","timestamp":1522244315000},"page":"219-230","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonale Hypertonie bei Kollagenosen"],"prefix":"10.1007","volume":"77","author":[{"given":"E. I.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"443_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","volume":"35","author":"ET Koh","year":"1996","unstructured":"Koh ET, Lee P, Gladman DD et\u00a0al (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989\u2013993","journal-title":"Br J Rheumatol"},{"key":"443_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/art.10775","volume":"48","author":"V Steen","year":"2003","unstructured":"Steen V, Medsger TA Jr. (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516\u2013522","journal-title":"Arthritis Rheum"},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944","journal-title":"Ann Rheum Dis"},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL et\u00a0al (2015) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir\u00a0J 46:903\u2013975","journal-title":"Eur Respir J"},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"M Humbert","year":"2006","unstructured":"Humbert M, Sitbon O, Chaouat A et\u00a0al (2006) Pulmonary arterial hypertension in France: results from a\u00a0national registry. Am J Respir Crit Care Med 173:1023\u20131030","journal-title":"Am J Respir Crit Care Med"},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.100245","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac J, Airo P, Meune C et\u00a0al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J\u00a0Rheumatol 37:2290\u20132298","journal-title":"J Rheumatol"},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1002\/art.21433","volume":"52","author":"E Hachulla","year":"2005","unstructured":"Hachulla E, Gressin V, Guillevin L et\u00a0al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a\u00a0French nationwide prospective multicenter study. Arthritis Rheum 52:3792\u20133800","journal-title":"Arthritis Rheum"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","volume":"62","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, St George D, Coleiro B et\u00a0al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a\u00a0registry approach. Ann Rheum Dis 62:1088\u20131093","journal-title":"Ann Rheum Dis"},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R, Kiely DG, Peacock AJ et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151\u2013157","journal-title":"Am J Respir Crit Care Med"},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1183\/09031936.00106008","volume":"34","author":"MJ Overbeek","year":"2009","unstructured":"Overbeek MJ, Vonk MC, Boonstra A et\u00a0al (2009) Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a\u00a0distinctive vasculopathy. Eur Respir\u00a0J 34:371\u2013379","journal-title":"Eur Respir J"},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","volume":"38","author":"P Dorfmuller","year":"2007","unstructured":"Dorfmuller P, Humbert M, Perros F et\u00a0al (2007) Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38:893\u2013902","journal-title":"Hum Pathol"},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Grunig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340\u20131349","journal-title":"Ann Rheum Dis"},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","volume":"27","author":"MH Williams","year":"2006","unstructured":"Williams MH, Handler CE, Akram R et al (2006) Role of N\u2011terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart\u00a0J 27:1485\u20131494","journal-title":"Eur Heart J"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.23187","volume":"58","author":"Y Allanore","year":"2008","unstructured":"Allanore Y, Borderie D, Avouac J et al (2008) High N\u2011terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58:284\u2013291","journal-title":"Arthritis Rheum"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/art.38172","volume":"65","author":"D Khanna","year":"2013","unstructured":"Khanna D, Gladue H, Channick R et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65:3194\u20133201","journal-title":"Arthritis Rheum"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/annrheumdis-2015-207336","volume":"75","author":"S Sanges","year":"2016","unstructured":"Sanges S, Launay D, Rhee RL et al (2016) A prospective study of the 6\u202fmin walk test as a\u00a0surrogate marker for haemodynamics in two independent cohorts of treatment-naive systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 75:1457\u20131465","journal-title":"Ann Rheum Dis"},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/heartjnl-2016-309981","volume":"103","author":"D Dumitrescu","year":"2017","unstructured":"Dumitrescu D, Nagel C, Kovacs G et\u00a0al (2017) Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 103:774\u2013782","journal-title":"Heart"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1378\/chest.08-3042","volume":"136","author":"E Hachulla","year":"2009","unstructured":"Hachulla E, Launay D, Mouthon L et\u00a0al (2009) Is pulmonary arterial hypertension really a\u00a0late complication of systemic sclerosis? Chest 136:1211\u20131219","journal-title":"Chest"},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38029","volume":"65","author":"G Lefevre","year":"2013","unstructured":"Lefevre G, Dauchet L, Hachulla E et al (2013) Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a\u00a0systematic review and meta-analysis. Arthritis Rheum 65:2412\u20132423","journal-title":"Arthritis Rheum"},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1183\/09031936.00145608","volume":"34","author":"G Kovacs","year":"2009","unstructured":"Kovacs G, Berghold A, Scheidl S et\u00a0al (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a\u00a0systematic review. Eur Respir\u00a0J 34:888\u2013894","journal-title":"Eur Respir J"},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.37838","volume":"65","author":"CJ Valerio","year":"2013","unstructured":"Valerio CJ, Schreiber BE, Handler CE et\u00a0al (2013) Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 65:1074\u20131084","journal-title":"Arthritis Rheum"},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1183\/13993003.00990-2016","volume":"48","author":"A Stamm","year":"2016","unstructured":"Stamm A, Saxer S, Lichtblau M et\u00a0al (2016) Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir\u00a0J 48:1658\u20131667","journal-title":"Eur Respir J"},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Galie N, Barbera JA et al (2017) Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 76:1219\u20131227","journal-title":"Ann Rheum Dis"},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1378\/chest.123.2.344","volume":"123","author":"SM Kawut","year":"2003","unstructured":"Kawut SM, Taichman DB, Archer-Chicko CL et al (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123:344\u2013350","journal-title":"Chest"},{"key":"443_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/ard.2005.048967","volume":"65","author":"CP Denton","year":"2006","unstructured":"Denton CP, Humbert M, Rubin L et al (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a\u00a0subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336\u20131340","journal-title":"Ann Rheum Dis"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/hrt.2005.069484","volume":"92","author":"MH Williams","year":"2006","unstructured":"Williams MH, Das C, Handler CE et\u00a0al (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926\u2013932","journal-title":"Heart"},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/rheumatology\/kep398","volume":"49","author":"D Launay","year":"2010","unstructured":"Launay D, Sitbon O, Le Pavec J et al (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 49:490\u2013500","journal-title":"Rheumatology (Oxford)"},{"key":"443_CR28","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M et\u00a0al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985\u20133993","journal-title":"Arthritis Rheum"},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a\u00a0report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"443_CR31","first-page":"831","volume":"151","author":"DJ Abraham","year":"1997","unstructured":"Abraham DJ, Vancheeswaran R, Dashwood MR et al (1997) Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151:831\u2013841","journal-title":"Am J Pathol"},{"key":"443_CR32","first-page":"1838","volume":"21","author":"R Vancheeswaran","year":"1994","unstructured":"Vancheeswaran R, Magoulas T, Efrat G et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets\u2014a marker of fibrosis or vascular dysfunction? J\u00a0Rheumatol 21:1838\u20131844","journal-title":"J Rheumatol"},{"key":"443_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1755-5922.2011.00279.x","volume":"30","author":"DB Badesch","year":"2012","unstructured":"Badesch DB, Feldman J, Keogh A et al (2012) ARIES-3: ambrisentan therapy in a\u00a0diverse population of patients with pulmonary hypertension. Cardiovasc Ther 30:93\u201399","journal-title":"Cardiovasc Ther"},{"key":"443_CR34","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G et\u00a0al (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J\u00a0Rheumatol 34:2417\u20132422","journal-title":"J Rheumatol"},{"key":"443_CR35","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA et\u00a0al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894\u20132903","journal-title":"Circulation"},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"M Humbert","year":"2017","unstructured":"Humbert M, Coghlan JG, Ghofrani HA et al (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76:422\u2013426","journal-title":"Ann Rheum Dis"},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, Mcgoon MD et\u00a0al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425\u2013434","journal-title":"Ann Intern Med"},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N et\u00a0al (2002) Inhaled iloprost for severe pulmonary hypertension. N\u00a0Engl J Med 347:322\u2013329","journal-title":"N Engl J Med"},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.126.2.420","volume":"126","author":"RJ Oudiz","year":"2004","unstructured":"Oudiz RJ, Schilz RJ, Barst RJ et\u00a0al (2004) Treprostinil, a\u00a0prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420\u2013427","journal-title":"Chest"},{"key":"443_CR40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02493-2016","author":"S Gaine","year":"2017","unstructured":"Gaine S, Chin K, Coghlan G et al (2017) Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir\u00a0J. \n                    https:\/\/doi.org\/10.1183\/13993003.02493-2016","journal-title":"Eur Respir J"},{"key":"443_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","volume":"129","author":"KM Olsson","year":"2014","unstructured":"Olsson KM, Delcroix M, Ghofrani HA et\u00a0al (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129:57\u201365","journal-title":"Circulation"},{"key":"443_CR42","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","volume":"132","author":"IR Preston","year":"2015","unstructured":"Preston IR, Roberts KE, Miller DP et al (2015) Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation 132:2403\u20132411","journal-title":"Circulation"},{"key":"443_CR43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbrc.2006.08.109","volume":"349","author":"C Suzuki","year":"2006","unstructured":"Suzuki C, Takahashi M, Morimoto H et\u00a0al (2006) Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun 349:781\u2013788","journal-title":"Biochem Biophys Res Commun"},{"key":"443_CR44","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.healun.2010.08.004","volume":"29","author":"JD Christie","year":"2010","unstructured":"Christie JD, Edwards LB, Kucheryavaya AY et al (2010) The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report\u20142010. J\u00a0Heart Lung Transpl 29:1104\u20131118","journal-title":"J Heart Lung Transpl"},{"key":"443_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.healun.2016.09.001","volume":"35","author":"RD Yusen","year":"2016","unstructured":"Yusen RD, Edwards LB, Dipchand AI et al (2016) The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report\u20142016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 35:1170\u20131184","journal-title":"J. Heart. Lung. Transplant."},{"key":"443_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M et al (2010) Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:164\u2013172","journal-title":"Circulation"},{"key":"443_CR47","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.10-0260","volume":"138","author":"L Chung","year":"2010","unstructured":"Chung L, Liu J, Parsons L et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a\u00a0unique phenotype. Chest 138:1383\u20131394","journal-title":"Chest"},{"key":"443_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","volume":"167","author":"KP Kuhn","year":"2003","unstructured":"Kuhn KP, Byrne DW, Arbogast PG et\u00a0al (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167:580\u2013586","journal-title":"Am J Respir Crit Care Med"},{"key":"443_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1054\/jcaf.2003.51","volume":"9","author":"F Fernandes","year":"2003","unstructured":"Fernandes F, Ramires FJ, Arteaga E et\u00a0al (2003) Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J\u00a0Card Fail 9:311\u2013317","journal-title":"J Card Fail"},{"issue":"Suppl 5","key":"443_CR50","doi-asserted-by":"publisher","first-page":"v42","DOI":"10.1093\/rheumatology\/ken284","volume":"47","author":"A Vonk Noordegraaf","year":"2008","unstructured":"Vonk Noordegraaf A, Naeije R (2008) Right ventricular function in scleroderma-related pulmonary hypertension. Rheumatology (Oxford) 47(Suppl 5):v42\u2013v43","journal-title":"Rheumatology (Oxford)"},{"key":"443_CR51","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.24267","volume":"60","author":"SC Mathai","year":"2009","unstructured":"Mathai SC, Hummers LK, Champion HC et\u00a0al (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569\u2013577","journal-title":"Arthritis Rheum"},{"key":"443_CR52","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I et\u00a0al (2013) Updated clinical classification of pulmonary hypertension. J\u00a0Am Coll Cardiol 62:D34\u2013D41","journal-title":"J Am Coll Cardiol"},{"key":"443_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/art.1780350709","volume":"35","author":"VD Steen","year":"1992","unstructured":"Steen VD, Graham G, Conte C et\u00a0al (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765\u2013770","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0443-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:52:19Z","timestamp":1553734339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0443-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"assertion":[{"value":"28 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.I.\u00a0Schwarz und S.\u00a0Ulrich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}